Sorafenib, a clinical kinase inhibitor, attenuates Streptococcus pneumoniae pathogenesis and reduces disease progression in vivo

ABSTRACT Streptococcus pneumoniae is an opportunistic respiratory commensal bacterium and leading cause of pneumonia, meningitis, and sepsis, resulting in over a million deaths annually, particularly in children aged under 5. The rapid spread of macrolide-resistant strains led the WHO to designate S...

Cijeli opis

Bibliografski detalji

Glavni autori:	Joel Abraham, Aswathy C. Sagilkumar, Himani Dhyani, Charmi M. Panchal, Shaheena Aziz, M. K. Priyadatha, Aan Ruth, Keerthana Bhaskaran, Sivakumar Krishnankutty Chandrika, S. Shaima, Rosemol Varghese, Ayyanraj Neeravi, Balaji Veeraragavan, Nagarjun Narayanaswamy, Sandhya Ganesan, Karthik Subramanian
Format:	Artigo
Jezik:	Inglês
Izdano:	American Society for Microbiology 2026-07-01
Serija:	mBio
Teme:	Streptococcus pneumoniae serine threonine kinase StkP sorafenib antimicrobial resistance drug repurposing
Online pristup:	https://journals.asm.org/doi/10.1128/mbio.00618-26
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!